Veraxa Biotech AGNASDAQ: VRXA

VERAXA Biotech (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures

· Issued by Veraxa Biotech AG

Summary by 6ix AI

Shareholders of VERAXA Biotech, which develops antibody-based cancer therapeutics, approved all proposals at its Extraordinary General Meeting. More than 99.94% of votes cast were in favor, with 72.20% of the company's outstanding share capital represented.

Key details

  • Shareholders approved conditional share capital, meaning shares that can be issued later, for shareholder options and warrants.
  • Shareholders approved a capital band, which lets the share capital be changed within set limits, running through December 31, 2030.
  • The maximum size of the board of directors rises from five to seven members.
  • VERAXA Biotech says the new framework is intended to give it more flexibility for potential acquisitions, strategic collaborations, investment projects, capital markets activities and development of its BiTAC technology platform and oncology pipeline.

6ix AI wrote this summary from the release below and checked it against the release.

Featured Image

Austin, Texas, United States, July 28th, 2026, NewsDirect

VERAXA Biotech (NASDAQ: VRXA) announced that shareholders overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in favor and 72.20% of the company's outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030 and an increase in the maximum size of the board of directors from five to seven members.

The company said the enhanced corporate and financing framework is intended to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital markets activities and continued development of its BiTAC(R) technology platform and oncology pipeline. Management said the vote reflects strong shareholder support for VERAXA's strategy of advancing antibody-based cancer therapeutics while pursuing long-term value creation.

To view the full press release, visit https://ibn.fm/qfL87

About VERAXA Biotech AG

At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.

BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA

Contact
IBNwww.InvestorBrandNetwork.comEditor@InvestorBrandNetwork.com

Veraxa Biotech AG on 6ix

Story so far

Earlier from Veraxa Biotech

Later from Veraxa Biotech

All Veraxa Biotech news releases